scPharmaceuticals Inc (SCPH)
3.49
+0.13
(+3.87%)
USD |
NASDAQ |
Nov 21, 16:00
3.31
-0.18
(-5.16%)
After-Hours: 20:00
scPharmaceuticals Enterprise Value: 127.75M for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 127.75M |
| November 19, 2024 | 135.76M |
| November 18, 2024 | 127.25M |
| November 15, 2024 | 132.75M |
| November 14, 2024 | 127.75M |
| November 13, 2024 | 155.27M |
| November 12, 2024 | 156.27M |
| November 11, 2024 | 171.28M |
| November 08, 2024 | 170.03M |
| November 07, 2024 | 175.79M |
| November 06, 2024 | 176.79M |
| November 05, 2024 | 163.28M |
| November 04, 2024 | 161.28M |
| November 01, 2024 | 163.28M |
| October 31, 2024 | 167.28M |
| October 30, 2024 | 182.79M |
| October 29, 2024 | 181.29M |
| October 28, 2024 | 178.29M |
| October 25, 2024 | 169.78M |
| October 24, 2024 | 168.78M |
| October 23, 2024 | 178.29M |
| October 22, 2024 | 180.29M |
| October 21, 2024 | 180.79M |
| October 18, 2024 | 186.30M |
| October 17, 2024 | 179.29M |
| Date | Value |
|---|---|
| October 16, 2024 | 180.29M |
| October 15, 2024 | 172.79M |
| October 14, 2024 | 169.78M |
| October 11, 2024 | 171.28M |
| October 10, 2024 | 163.78M |
| October 09, 2024 | 156.77M |
| October 08, 2024 | 158.52M |
| October 07, 2024 | 163.28M |
| October 04, 2024 | 173.79M |
| October 03, 2024 | 176.79M |
| October 02, 2024 | 177.79M |
| October 01, 2024 | 170.28M |
| September 30, 2024 | 187.80M |
| September 27, 2024 | 232.12M |
| September 26, 2024 | 222.61M |
| September 25, 2024 | 233.62M |
| September 24, 2024 | 240.12M |
| September 23, 2024 | 242.12M |
| September 20, 2024 | 260.64M |
| September 19, 2024 | 264.64M |
| September 18, 2024 | 273.14M |
| September 17, 2024 | 277.14M |
| September 16, 2024 | 277.14M |
| September 13, 2024 | 276.14M |
| September 12, 2024 | 267.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.68M
Minimum
Dec 11 2019
341.11M
Maximum
May 12 2023
135.58M
Average
124.80M
Median
Jun 03 2024
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.745M |
| Palatin Technologies Inc | 15.49M |
| iBio Inc | 9.932M |
| Theriva Biologics Inc | -12.74M |
| Oragenics Inc | 2.485M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.10M |
| Revenue (Quarterly) | 10.03M |
| Total Expenses (Quarterly) | 28.17M |
| EPS Diluted (Quarterly) | -0.75 |
| Gross Profit Margin (Quarterly) | 66.98% |
| Profit Margin (Quarterly) | -350.1% |
| Earnings Yield | -54.44% |
| Normalized Earnings Yield | -46.42 |